JNJ or MRK: One Dividend Is Built to Last, One Faces a Reckoning
Both JNJ and MRK have surged in 2026, but a looming patent cliff and a balance sheet loaded with acquisition debt mean one of these pharma dividends faces a reckoning that retirement investors cannot afford to ignore.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) or Merck (NYSE:MRK): which pharma dividend looks stronger for retirement-focused income right now? Both stocks have rallied hard in 2026. Merck is up 40.18% year to date and J&J is up 29.1%, so the easy price gains are already secured. The question now is which payout holds up through the next decade of patent expirations. I compared them on dividend strength, patent cliff exposure, and balance sheet risk.
Dividend Strength: J&J Raises Like Clockwork
Merck offers the higher starting yield at 2.22%, against 1.96% for J&J. Merck’s annualized forward dividend is $3.4 per share on a $0.85 quarterly payment. J&J’s is $5.36 per share after a 3.1% raise to $1.34 declared April 14, 2026.
J&J’s dividend history shows a raise every year from 2009 through 2026, climbing from $0.46 to $1.34 per quarter. Merck has stepped up recently, from $0.77 to $0.81 to $0.85, yet its record includes a flat stretch at $0.38 from 2010 into 2011.
Coverage visibility also favors J&J. It produced $19.7 billion of free cash flow in 2025 and guides to a full-year figure “approaching $21 billion.” Merck’s management said, “We remain committed to the dividend with the goal of increasing it over time,” but supplied no payout ratio or free cash flow figure. Winner: J&J.
Patent Cliff Exposure: Merck Faces the Steeper Climb
Loss of exclusivity means cheaper generic or biosimilar copies can enter the market, and sales of the original drug drop fast. That lost cash is the same cash that funds the dividend.
J&J is living through it now. Stelara sales fell 55.7% in the second quarter, yet total sales rose 5.6% operationally. Stelara had shrunk to 4% of Innovative Medicine, and the rest of that business grew over 14%. Tremfya grew 71% to its first $2 billion quarter, and J&J counts 28 products and platforms each above $1 billion in annual sales.
Merck’s exposure is concentrated. Keytruda represents nearly half of pharma revenue, and the franchise grew just 4% to $8.4 billion last quarter as management noted moderating U.S. growth. Three Phase 3 oncology trials failed: LITESPARK-012, KEYNOTE-975 and KEYNOTE-866. CEO Rob Davis calls the transition “more of a hill than a cliff,” mentioning more than 20 new products and “greater than $70 billion of commercial opportunity,” with growth resuming in the early 2030s. Positive sac-TMT data in endometrial cancer helps, but J&J has already taken its hit while Merck’s still lies ahead. Winner: J&J.
Balance Sheet Risk: Merck’s Deal Spree Costs More
J&J ended the second quarter with about $21 billion of cash against $49 billion of debt, a net debt position near $28 billion. Litigation is a ongoing drag, including a $330M first-quarter charge, and the Orthopaedics separation adds execution risk. Those costs remain small relative to free cash flow. Pressuring the payout would take a litigation outcome far larger than anything recorded so far.
Merck’s burden is self-inflicted. The Cidara and Terns deals carry roughly $14.8B in combined one-time charges, and financing costs push full-year other expense to about $1.4 billion. Management says “Business development remains a high priority.” Another large deal stacked on Keytruda erosion is the scenario that pressures the dividend. Winner: J&J.
Verdict: J&J Owns the Retirement Income Slot
J&J wins outright. It has a longer raise record, disclosed cash coverage, and a patent cliff already in the rearview. Merck still offers the higher yield and a cheaper multiple: its forward P/E is 15 against 21 for J&J, and analysts target $155.76 versus a $144.54 share price. Next up: J&J’s Enterprise Business Review on Dec 8, 2026 and whether Merck lifts its payout after holding it at $0.85 all year.
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
